We are live on ! Find out more
OBX icon

Obsidian Therapeutics

12.22 USD
-0.34
2.71%
At close Updated Nov 16, 11:36 AM EST
1 day
-2.71%
5 days
-8.74%
1 month
3.82%
3 months
-30.33%
6 months
-64.06%
Year to date
-64.06%
1 year
-64.06%
5 years
-64.06%
10 years
-64.06%
 

About: Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
Business Wire
3 days ago
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026, highlighting recent progress and business updates. “2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350.
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Neutral
Business Wire
10 days ago
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive updated results in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel (amsoki-ce.
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
Neutral
Business Wire
1 month ago
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki.
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Neutral
Seeking Alpha
2 months ago
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Obsidian Therapeutics is rated Hold due to overvaluation despite promising cell therapy technology targeting solid tumors. OBX-115, the lead asset, shows strong early efficacy and safety in advanced melanoma, but is only in Phase 1/2 trials. Current $1.1B market cap implies high expectations; risk-adjusted fair value is $10.16/share versus ~$17.00 trading price.
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Price charts implemented using Lightweight Charts™